Clinical trials: NSCLC (non-small Cell Lung Cancer)
Lung Neoplasms, Non-Small Cell Lung Cancer, Postoperative Complications
Smartphone-based Remote Symptom Monitoring to Improve Postoperative Rehabilitation Exercise Adherence After Video-assisted Thoracic Surgery (VATS) for Lung Cancer
Brief Summary: This randomized controlled trial aims to evaluate whether active remote symptom monitoring and management via a smartphone app utilizing electronic patient-reported outcomes (ePRO) can improve adherence to…
- Conditions
- Lung Neoplasms, Non-Small Cell Lung Cancer, Postoperative Complications, Patient Reported Outcome Measures, Telerehabilitation
- Trial name
- NCT05990946
- Testing
- ePRO based Remote Symptom Management provide by a mobile phone app
- Where
- China
- Volunteers
- 736 people
- Sponsor
- Zhongshan People's Hospital, Guangdong, China
Advanced Non-squamous NSCLC
A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC
The purpose of this study is to estimate the difference in objective response rates between each paclitaxel/carboplatin plus AMG 706 arm (Arm A and B) and paclitaxel/carboplatin plus bevacizumab arm (Arm C) in subjects with…
- Trial name
- NCT00369070
- Testing
- Bevacizumab, AMG 706, Paclitaxel
- Volunteers
- 186 people
- Sponsor
- Amgen
Non-small Cell Lung Cancer
Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery
This study is a multicenter, prospective, and observational clinical study aimed at exploring whether the 3-year DFS in the Huaier group is not inferior to the control group receiving standard platinum dual-drug chemotherapy.
- Trial name
- NCT06109454
- Testing
- Huaier granule, Control
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Non-small Cell Lung Cancer Stage III, KRAS P.G12C
Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
Open-label, non-randomised, exploratory, phase II, multi-centre clinical trial. 43 unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12C non-small cell lung cancer patients will be enrolled in this trial to evaluate the…
- Trial name
- MERIT-lung (NCT05398094)
- Testing
- Sotorasib
- Where
- 20 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Fundación GECP
Carcinoma, Non-Small-Cell Lung
Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer
The objective of this phase III trial is to establish statistical equivalence in terms of efficacy (best overall response rate [ORR], proportion of patients with complete response [CR] plus partial response [PR]) until 18 weeks…
- Trial name
- NCT02272413
- Testing
- BI 695502, Avastin
- Where
- 189 sites in United States, Argentina and 26 more
- Volunteers
- 671 people
- Sponsor
- Boehringer Ingelheim
Non Small Cell Lung Cancer
Pembrolizumab in Elderly Patients With Advanced Lung Cancer
This is a multi-center phase II trial of intravenous (IV) Pembrolizumab MK-3475 in subjects older than 70 years with advanced Non-small cell Lung Cancer (NSCLC) expressing Programmed death-ligand 1 (PD-L1).
- Trial name
- NCT03293680
- Testing
- Pembrolizumab
- Where
- 12 sites in Spain
- Volunteers
- 83 people
- Sponsor
- Spanish Lung Cancer Group
Lung Cancer, Sarcopenia
Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC
This study evaluate the association of body composition (mainly free-fat mass), clinical and biochemical parameters with development of toxicity in patients under treatment with Carboplatin/Paclitaxel in advanced NSCLC.
- Conditions
- Lung Cancer, Sarcopenia, Toxicity
- Trial name
- NCT02734069
- Testing
- Carboplatin
- Where
- Mexico
- Volunteers
- 132 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Non-small Cell Lung Cancer
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung…
- Trial name
- RELATIVITY1093 (NCT06561386)
- Testing
- Nivolumab, Relatlimab, Pembrolizumab
- Where
- 329 sites in United States, Argentina and 29 more
- Volunteers
- 1,000 people
- Sponsor
- Bristol-Myers Squibb
Stage IV Non-small Cell Lung Cancer
Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer
This phase I trial studies the side effects and best dose of exemestane in combination with pemetrexed disodium and carboplatin in treating post-menopausal women with stage IV non-small cell lung cancer.
- Trial name
- NCT01664754
- Testing
- exemestane, pemetrexed disodium, carboplatin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Non-Small-Cell Lung Cancer
A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
30-40% of patients with lung cancer will develop bone metastases during the course of their disease, which can lead to pain, decreased mobility and skeletal complications.
- Trial name
- NCT00172042
- Testing
- Zoledronic acid 4 mg
- Where
- 69 sites in Belgium, China and 13 more
- Volunteers
- 437 people
- Sponsor
- Novartis Pharmaceuticals
EGFR Gene Mutation, Recurrent Non-Small Cell Lung Carcinoma
Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer
This phase I/II trial studies the best dose and side effects of nimotuzumab when giving together with nivolumab and to see how well they work in treating patients with non-small cell lung cancer that has spread to other places in…
- Conditions
- EGFR Gene Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT02947386
- Testing
- Laboratory Biomarker Analysis, Nimotuzumab, Nivolumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Roswell Park Cancer Institute
Non Small Cell Lung Carcinoma
Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
The primary aim of this non interventional study is to assess the independent prognostic role on overall survival of primary tumour 18F-FDG uptake value (SUVmax) measured on 18fluorodeoxyglucose positron emission tomography…
- Trial name
- NCT00759382
- Where
- 6 sites in Belgium
- Volunteers
- 340 people
- Sponsor
- European Lung Cancer Working Party
Lung Cancer
Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer
The purpose of this study is to determine the antitumor activity (response rate, time to tumor progression, survival) and safety of docetaxel in combination with talabostat in patients with advanced non-small cell lung cancer…
- Trial name
- NCT00080080
- Testing
- talabostat (PT-100) tablets, Docetaxel
- Where
- 10 sites in United States
- Sponsor
- Point Therapeutics
Non-small Cell Lung Cancer
Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer
This study will help researchers test the safety of hypofractionated dose of radiotherapy (HySBst) at different dose levels before or after chemo-radiation for Non Small Cell Lung Cancer.
- Trial name
- HySBst (NCT02252796)
- Testing
- Hypofractionated Stereotactic Boost, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- West Virginia University
Non-small Cell Lung Cancer
Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy
The purpose of this research study is to find out how well cetuximab works in treating NSCLC in patients who have been previously treated with a class of drug called tyrosine kinase inhibitor (TKI).
- Trial name
- NCT00694603
- Testing
- Cetuximab
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Lecia V. Sequist
Non Small Cell Lung Cancer
Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
Determine the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of ACY 241 in combination with nivolumab.
- Trial name
- NCT02635061
- Testing
- ACY-241, Nivolumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Celgene
NSCLC, Renal Cell Carcinoma
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
This study is designed to see if we can lower the chance of side effects from radiation in patients with breast, kidney, small cell lung cancer, non-small cell lung cancer or melanoma that has spread to the brain and who are also…
- Conditions
- NSCLC, Renal Cell Carcinoma, Breast Carcinoma, Melanoma
- Trial name
- HYPOGRYPHE (NCT05703269)
- Testing
- single fraction stereotactic radiosurgery (SSRS), fractionated stereotactic radiosurgery (FSRS)
- Where
- 34 sites in United States
- Volunteers
- 58 people
- Sponsor
- Wake Forest University Health Sciences
Lung Cancer (NSCLC), Lung Cancer (SCLC)
Multi-Omics Prediction of Radiation Lung Injury in Immunotherapy-Treated Lung Cancer Patients
This prospective study aims to develop a multi-omics-based predictive model for radiation pneumonitis in lung cancer patients receiving sequential immunotherapy and thoracic radiotherapy.
- Trial name
- NCT07742800
- Testing
- No Intervention: Observational Cohort
- Where
- China
- Volunteers
- 160 people
- Sponsor
- HAN GUANG
Advanced Solid Tumor, Non-Small Cell Lung Cancer
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
This phase 1 open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CHS-006 in combination with toripalimab in 2 phases.
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- NCT05757492
- Testing
- CHS-006 (anti-TIGIT), toripalimab (anti-PD-1)
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Coherus Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer
The study objective is to evaluate the maximum tolerated dose, safety and efficacy of patupilone in patients with NSCLC who have progressed after prior chemotherapy.
- Trial name
- NCT00171834
- Testing
- Patupilone
- Where
- 4 sites in United States
- Volunteers
- 89 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.